APA
McNeill R. S., Canoutas D. A., Stuhlmiller T. J., Dhruv H. D., Irvin D. M., Bash R. E., Angus S. P., Herring L. E., Simon J. M., Skinner K. R., Limas J. C., Chen X., Schmid R. S., Siegel M. B., Van Swearingen A. E. D., Hadler M. J., Sulman E. P., Sarkaria J. N., Anders C. K., Graves L. M., Berens M. E., Johnson G. L. & Miller C. R. (20180627). Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. : Neuro-oncology.
Chicago
McNeill Robert S, Canoutas Demitra A, Stuhlmiller Timothy J, Dhruv Harshil D, Irvin David M, Bash Ryan E, Angus Steven P, Herring Laura E, Simon Jeremy M, Skinner Kasey R, Limas Juanita C, Chen Xin, Schmid Ralf S, Siegel Marni B, Van Swearingen Amanda E D, Hadler Michael J, Sulman Erik P, Sarkaria Jann N, Anders Carey K, Graves Lee M, Berens Michael E, Johnson Gary L and Miller C Ryan. 20180627. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. : Neuro-oncology.
Harvard
McNeill R. S., Canoutas D. A., Stuhlmiller T. J., Dhruv H. D., Irvin D. M., Bash R. E., Angus S. P., Herring L. E., Simon J. M., Skinner K. R., Limas J. C., Chen X., Schmid R. S., Siegel M. B., Van Swearingen A. E. D., Hadler M. J., Sulman E. P., Sarkaria J. N., Anders C. K., Graves L. M., Berens M. E., Johnson G. L. and Miller C. R. (20180627). Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. : Neuro-oncology.
MLA
McNeill Robert S, Canoutas Demitra A, Stuhlmiller Timothy J, Dhruv Harshil D, Irvin David M, Bash Ryan E, Angus Steven P, Herring Laura E, Simon Jeremy M, Skinner Kasey R, Limas Juanita C, Chen Xin, Schmid Ralf S, Siegel Marni B, Van Swearingen Amanda E D, Hadler Michael J, Sulman Erik P, Sarkaria Jann N, Anders Carey K, Graves Lee M, Berens Michael E, Johnson Gary L and Miller C Ryan. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. : Neuro-oncology. 20180627.